111 related articles for article (PubMed ID: 21360537)
1. Prospective comparison of peritumoral and subareolar injection of blue dye alone, for identification of sentinel lymph nodes in patients with early stage breast cancer.
Kaklamanos IG; Birbas K; Syrigos K; Bonatsos VG; Bonatsos G
J Surg Oncol; 2011 Jul; 104(1):37-40. PubMed ID: 21360537
[TBL] [Abstract][Full Text] [Related]
2. Concordance of peritumoral technetium 99m colloid and subareolar blue dye injection in breast cancer sentinel lymph node biopsy.
Kargozaran H; Shah M; Li Y; Beckett L; Gandour-Edwards R; Schneider PD; Khatri VP
J Surg Res; 2007 Nov; 143(1):126-9. PubMed ID: 17950081
[TBL] [Abstract][Full Text] [Related]
3. Intradermal radioisotope is superior to peritumoral blue dye or radioisotope in identifying breast cancer sentinel nodes.
Lin KM; Patel TH; Ray A; Ota M; Jacobs L; Kuvshinoff B; Chung M; Watson M; Ota DM
J Am Coll Surg; 2004 Oct; 199(4):561-6. PubMed ID: 15454139
[TBL] [Abstract][Full Text] [Related]
4. Intraoperative subareolar injection of 99mTc-labeled sulfur colloid results in consistent sentinel lymph node identification.
Zogakis TG; Wetherille RE; Christensen RD; Ose KJ; Friedman JD; Colbert M; Svendsen CA; Sanan OK; Tuttle TM
Ann Surg Oncol; 2005 Feb; 12(2):167-72. PubMed ID: 15827798
[TBL] [Abstract][Full Text] [Related]
5. Validation of subareolar and periareolar injection techniques for breast sentinel lymph node biopsy.
Chagpar A; Martin RC; Chao C; Wong SL; Edwards MJ; Tuttle T; McMasters KM
Arch Surg; 2004 Jun; 139(6):614-8; discussion 618-20. PubMed ID: 15197087
[TBL] [Abstract][Full Text] [Related]
6. Methylene blue dye--a safe and effective alternative for sentinel lymph node localization.
Varghese P; Abdel-Rahman AT; Akberali S; Mostafa A; Gattuso JM; Carpenter R
Breast J; 2008; 14(1):61-7. PubMed ID: 18186867
[TBL] [Abstract][Full Text] [Related]
7. Double mapping with subareolar blue dye and peritumoral green dye injections decreases the false-negative rate of dye-only sentinel node biopsy for early breast cancer: 2-site injection is more accurate than 1-site injection.
Anan K; Mitsuyama S; Kuga H; Saimura M; Tanabe Y; Suehara N; Matsunaga H; Nishihara K; Abe Y; Iwashita T; Ihara T; Tamae K; Ono M; Toyoshima S
Surgery; 2006 May; 139(5):624-9. PubMed ID: 16701094
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo sentinel lymph node mapping in colon cancer: improving the accuracy of pathologic staging?
Smith J; Hwang H; Wiseman KW; Filipenko D; Phang PT
Am J Surg; 2006 May; 191(5):665-8. PubMed ID: 16647356
[TBL] [Abstract][Full Text] [Related]
9. A prospective trial comparing 1% lymphazurin vs 1% methylene blue in sentinel lymph node mapping of gastrointestinal tumors.
Soni M; Saha S; Korant A; Fritz P; Chakravarty B; Sirop S; Gayar A; Iddings D; Wiese D
Ann Surg Oncol; 2009 Aug; 16(8):2224-30. PubMed ID: 19484313
[TBL] [Abstract][Full Text] [Related]
10. Sentinel lymph node mapping of breast cancer: a case-control study of methylene blue tracer compared to isosulfan blue.
Eldrageely K; Vargas MP; Khalkhali I; Venegas R; Burla M; Gonzalez KD; Vargas HI
Am Surg; 2004 Oct; 70(10):872-5. PubMed ID: 15529840
[TBL] [Abstract][Full Text] [Related]
11. Sentinel lymph node detection in patients with early-stage breast cancer: comparison of periareolar and subdermal/peritumoral injection techniques.
Pelosi E; Bellò M; Giors M; Ala A; Giani R; Bussone R; Bisi G
J Nucl Med; 2004 Feb; 45(2):220-5. PubMed ID: 14960639
[TBL] [Abstract][Full Text] [Related]
12. Prospective randomized study comparing sentinel lymph node evaluation with standard pathologic evaluation for the staging of colon carcinoma: results from the United States Military Cancer Institute Clinical Trials Group Study GI-01.
Stojadinovic A; Nissan A; Protic M; Adair CF; Prus D; Usaj S; Howard RS; Radovanovic D; Breberina M; Shriver CD; Grinbaum R; Nelson JM; Brown TA; Freund HR; Potter JF; Peretz T; Peoples GE
Ann Surg; 2007 Jun; 245(6):846-57. PubMed ID: 17522508
[TBL] [Abstract][Full Text] [Related]
13. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
[TBL] [Abstract][Full Text] [Related]
14. [Sentinel lymph node detection in patients with early-stage breast cancer: which site of injection in 2011?].
Frati A; Delpech Y; Bricou A; Barranger E
Gynecol Obstet Fertil; 2011 Nov; 39(11):620-3. PubMed ID: 21873098
[TBL] [Abstract][Full Text] [Related]
15. The relative false negative rate of isosulfan blue in detecting sentinel lymph nodes in early breast cancer.
Kantaraksa N; Kongdan Y; Suvikapakornkul R; Wasutit Y; Chirappapha P; Lertsithichai P
J Med Assoc Thai; 2012 Feb; 95(2):181-5. PubMed ID: 22435247
[TBL] [Abstract][Full Text] [Related]
16. Sentinel lymph node mapping in breast cancer using subareolar injection of blue dye.
Kern KA
J Am Coll Surg; 1999 Dec; 189(6):539-45. PubMed ID: 10589589
[TBL] [Abstract][Full Text] [Related]
17. Subareolar versus peritumoral injection for location of the sentinel lymph node.
Klimberg VS; Rubio IT; Henry R; Cowan C; Colvert M; Korourian S
Ann Surg; 1999 Jun; 229(6):860-4; discussion 864-5. PubMed ID: 10363900
[TBL] [Abstract][Full Text] [Related]
18. [Usefulness of lymphatic mapping with sub-areolar injection of patent blue dye, in the typification of breast cancer].
Gallegos-Hernández JF; Chávez-García M
Rev Invest Clin; 2003; 55(4):407-11. PubMed ID: 14635604
[TBL] [Abstract][Full Text] [Related]
19. Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer.
Bauer TW; Spitz FR; Callans LS; Alavi A; Mick R; Weinstein SP; Bedrosian I; Fraker DL; Bauer TL; Czerniecki BJ
Ann Surg Oncol; 2002 Mar; 9(2):169-76. PubMed ID: 11888875
[TBL] [Abstract][Full Text] [Related]
20. Sentinel lymph node detection by intranipple injection of patent blue dye in breast cancer: a preliminary report of a feasibility study.
Zervoudis S; Iatrakis G; Paschopoulos M; Dousias V; Geahchan N; Stefos T; Pechlivani F; Navrozoglou I
Eur J Gynaecol Oncol; 2012; 33(3):304-5. PubMed ID: 22873105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
